Kiora Pharmaceuticals (NASDAQ:KPRX) Releases Earnings Results, Beats Estimates By $0.13 EPS

Kiora Pharmaceuticals (NASDAQ:KPRX) issued its earnings results on Friday. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.13, FiscalAI reports.

Kiora Pharmaceuticals Stock Performance

NASDAQ KPRX remained flat at $2.45 during trading hours on Friday. 40,835 shares of the company’s stock traded hands, compared to its average volume of 64,626. Kiora Pharmaceuticals has a one year low of $1.76 and a one year high of $4.18. The stock has a market cap of $10.85 million, a P/E ratio of -0.92 and a beta of -0.48. The firm has a fifty day moving average of $2.21 and a 200 day moving average of $2.17.

Hedge Funds Weigh In On Kiora Pharmaceuticals

Several large investors have recently bought and sold shares of KPRX. Two Sigma Investments LP acquired a new position in Kiora Pharmaceuticals in the third quarter valued at $33,000. Renaissance Technologies LLC boosted its stake in Kiora Pharmaceuticals by 71.0% in the fourth quarter. Renaissance Technologies LLC now owns 21,200 shares of the company’s stock valued at $42,000 after acquiring an additional 8,800 shares in the last quarter. Citadel Advisors LLC acquired a new position in Kiora Pharmaceuticals in the third quarter valued at $125,000. Alyeska Investment Group L.P. acquired a new position in Kiora Pharmaceuticals in the fourth quarter valued at $152,000. Finally, DRW Securities LLC boosted its stake in Kiora Pharmaceuticals by 199.2% in the fourth quarter. DRW Securities LLC now owns 110,282 shares of the company’s stock valued at $217,000 after acquiring an additional 73,417 shares in the last quarter. Institutional investors and hedge funds own 76.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Kiora Pharmaceuticals in a research note on Monday, April 27th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Kiora Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $10.00.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders.